Australian pharmaceutical firm Hatchtech has appointment Timothy Waugh as chief executive.
Waugh has worked in the pharmaceutical industry for 27 years and has spent the last 10 years with Roche in the US as a divisional vice president.
Paul Kelly, Hatchtech’s chairman, said: ‘Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercialising DeOvo for the global marketplace.’
DeOvo is a topical formulation of a known metalloprotease inhibitor and offer the potential for a head lice control treatment that requires only one application.
Waugh said he looks forward to working with Hatchtech’s Board and management team as it review the results of the Phase IIb study and plan for the next stages of its clinical development.
Waugh will join the Board of Hatchtech and will be based in New Jersey, US.
Hatchtech appoints Tim Waugh as ceo
Formerly with Roche in the US as a divisional vice president
